Literature DB >> 9813289

Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions.

S Zhuang1, J Kittler, E V Grigorenko, M T Kirby, L J Sim, R E Hampson, S R Childers, S A Deadwyler.   

Abstract

The time course of changes across 21 days of continuous exposure to Delta9-tetrahydrocannabinol (Delta9-THC) was assessed for the level of cannabinoid receptor (CB1) mRNA expression in three different rat brain regions: cerebellum, hippocampus and corpus striatum. Expression levels of CB1 mRNA were determined using semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) following a protocol which included a gene standard, 28S ribonucleic acid protein (rRNA), for normalization of levels of RNA in the three different brain regions. The levels of CB1 mRNA were assessed in four different rats at each of seven time points (6 h, and 1, 2, 3, 7, 14 and 21 days) during a 21-day Delta9-THC one dose day-1 (10 mg kg-1) treatment regimen. In the cerebellum and hippocampus, CB1 mRNA levels were increased above vehicle control animals at 7 and 14 days of treatment. In the striatum the levels of CB1 transcripts were severely reduced from days 2-14. CB1 message expression in all three brain areas returned to vehicle control levels by day 21 of Delta9-THC treatment, a time at which behavioral tolerance has been previously reported. An additional measure, receptor stimulated GTPgammaS binding, performed over the same time period revealed differential desensitization within the 3 brain areas as a function of chronic exposure to Delta9-THC. Hippocampus was the earliest to desensitize decreasing to 35% of control by treatment day 7, followed by a decrease in the cerebellum to that same level on day 14 of treatment. The striatum showed only half that degree of desensitization (65%) over the entire 21-day treatment period. Comparisons suggests that CB1 message may be regulated by different effector systems in each of the three areas during chronic Delta9-THC exposure. Copyright 1998 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9813289     DOI: 10.1016/s0169-328x(98)00232-0

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  28 in total

1.  Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat.

Authors:  Shuangsong Hong; Gen Zheng; Xiaoyin Wu; Natasha T Snider; Chung Owyang; John W Wiley
Journal:  Gastroenterology       Date:  2010-11-09       Impact factor: 22.682

Review 2.  Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome.

Authors:  Didier Jutras-Aswad; Jennifer A DiNieri; Tibor Harkany; Yasmin L Hurd
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-02       Impact factor: 5.270

3.  Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety.

Authors:  Lauren C Harte-Hargrove; Diana L Dow-Edwards
Journal:  Behav Brain Res       Date:  2012-03-05       Impact factor: 3.332

4.  Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain.

Authors:  Emma Leishman; Ben Cornett; Karl Spork; Alex Straiker; Ken Mackie; Heather B Bradshaw
Journal:  Pharmacol Res       Date:  2016-04-22       Impact factor: 7.658

5.  Seizing an opportunity for the endocannabinoid system.

Authors:  Bradley E Alger
Journal:  Epilepsy Curr       Date:  2014-09       Impact factor: 7.500

Review 6.  CB1 and CB2 Receptor Pharmacology.

Authors:  Allyn C Howlett; Mary E Abood
Journal:  Adv Pharmacol       Date:  2017-06-12

7.  Systemic Blockade of the CB1 Receptor Augments Hippocampal Gene Expression Involved in Synaptic Plasticity but Perturbs Hippocampus-Dependent Learning Task.

Authors:  Kofi-Kermit A Horton; Anushka V Goonawardena; John Sesay; Allyn C Howlett; Robert E Hampson
Journal:  Cannabis Cannabinoid Res       Date:  2019-03-13

Review 8.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 9.  Role of cannabinoids and endocannabinoids in cerebral ischemia.

Authors:  Cecilia J Hillard
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  Transcriptomic and proteomic analyses of mouse cerebellum reveals alterations in RasGRF1 expression following in vivo chronic treatment with delta 9-tetrahydrocannabinol.

Authors:  Graziano Colombo; Francesco Rusconi; Tiziana Rubino; Angela Cattaneo; Enzo Martegani; Daniela Parolaro; Angela Bachi; Renata Zippel
Journal:  J Mol Neurosci       Date:  2008-06-27       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.